+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 13 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.

Age: 18Years +All GendersPhase 3
1452 locations
E

Actively Recruiting

The trial investigates how well AZD6234 works and its safety in adults who have Type 2 Diabetes Mellitus along with obesity or excess weight. This Phase III, global, randomized, double-blind study compares AZD6234 to a placebo to measure changes in body weight over 68 weeks of treatment. The study aims to better understand weight loss effects and related health changes in this population. Participants will be randomly assigned to one of three groups two different doses of AZD6234 or a placebo. The treatments are given by weekly subcutaneous injections. The study will last 68 weeks, during which participants receive their assigned injections and are monitored regularly for effectiveness and safety. Throughout the study, participants will attend multiple visits for evaluations, including body weight, waist circumference, blood pressure, and lab tests such as haemoglobin A1C and triglycerides. Some may undergo DXA scans to measure fat mass. Researchers will track changes from baseline to assess weight loss and metabolic effects. Safety and tolerability will also be monitored over the treatment period, which lasts about 68 weeks.

Age: 18Years +All GendersPhase 3
230 locations
P

Actively Recruiting

Researchers are conducting a multicenter, randomized, double-blind Phase 2 study to evaluate the pharmacodynamics, safety, and tolerability of a combination of QCZ484 and inclisiran compared to QCZ484 alone, inclisiran alone, and placebo in adults with hypertension and hypercholesterolemia. The study focuses on understanding how these treatments affect certain blood markers and blood pressure in this population. Participants receive a single dose of either the combination of QCZ484 and inclisiran, QCZ484 alone, inclisiran alone, or placebo on Day 1. The study lasts up to 12 months and includes a screening period with two visits to confirm eligibility, followed by the treatment administration at the baselinerandomization visit. After treatment, participants enter a safety follow-up phase, with an option to join an open-label extension study instead of the follow-up. During the study, participants undergo various assessments including measurements of PCSK9 and AGT levels at baseline and Month 3, blood pressure and LDL cholesterol levels at baseline, Month 3, and Month 6, along with monitoring for treatment-emergent adverse events and changes in laboratory tests and vital signs for up to 12 months. These evaluations help researchers understand the effects and safety of the treatments over time.

Age: 18Years - 75YearsAll GendersPhase 2
29 locations
E

Actively Recruiting

Researchers are evaluating the cardiovascular outcomes of elecoglipron compared with a placebo in adults with heart failure with preserved ejection fraction HFpEF or mildly reduced ejection fraction HFmrEF. This Phase III, randomized, double-blind, placebo-controlled study includes participants regardless of type 2 diabetes status who are also taking dapagliflozin along with other standard care treatments. Participants are randomly assigned to receive either elecoglipron tablets once daily or matching placebo tablets once daily. The study is conducted across multiple centers and follows a parallel-group design. The treatment period may last up to 42 months, during which the effects of elecoglipron on cardiovascular events and patient outcomes are assessed. Throughout the study, participants undergo regular evaluations to monitor their heart failure status, including assessments of cardiovascular death risk, hospitalization for heart failure, and urgent heart failure visits. Patient-reported outcomes are collected using questionnaires at baseline and at 52 weeks. Safety and efficacy are closely monitored over the extended treatment period to determine the impact of elecoglipron compared to placebo.

Age: 18Years +All GendersPhase 3
679 locations
T

Actively Recruiting

Researchers are evaluating the effects of vicadrostat combined with empagliflozin in adults with chronic heart failure who have a reduced left ventricular ejection fraction below 40%. Participants must have been diagnosed with chronic heart failure for at least three months and be in New York Heart Association classes II to IV. The study is a phase III, randomized, double-blind trial aimed at assessing whether this combination improves outcomes compared to placebo plus empagliflozin. Participants are randomly assigned to one of two groups with equal chance one group receives vicadrostat with empagliflozin tablets, and the other receives placebo with empagliflozin tablets. The study medicines are taken once daily for about six months up to three and a half years. Participants continue their regular heart failure treatments alongside the study drugs. The study monitors participants throughout this period, which can last up to 43 months. During the study, participants attend regular visits to the study site and may receive some follow-up calls. They answer questionnaires about their symptoms and overall well-being. Doctors record any worsening heart failure symptoms, hospitalizations due to heart failure, or deaths to compare the two groups. Health status and any side effects are regularly checked. The primary outcome is the time to first cardiovascular death, hospitalization for heart failure, or urgent heart failure visit.

Age: 18Years +All GendersPhase 3
594 locations
E

Actively Recruiting

Researchers are evaluating the effect and safety of orforglipron taken once daily in adults with Fontaine Stage II peripheral arterial disease PAD, a condition that causes symptoms like leg pain due to poor blood flow. The study is a phase 3 randomized, double-blind, placebo-controlled trial aiming to better understand how this treatment impacts walking ability and quality of life in this population. Participation is expected to last about 58 weeks. Participants are randomly assigned to receive either orforglipron or a placebo, both taken orally once daily. The study compares these two groups to assess changes in walking distances and other health measures over the course of the trial. This design helps evaluate the medications effect compared to no active treatment. During the study, participants undergo assessments including measuring maximum and pain-free walking distances, vascular quality of life via questionnaire, the six-minute walk test, blood markers like high-sensitivity C-reactive protein, and systolic blood pressure. These measurements occur at the start and after 52 weeks of treatment. Safety and effectiveness are monitored throughout, with overall participation lasting nearly a year.

Age: 18Years +All GendersPhase 3
169 locations
R

Actively Recruiting

Researchers are studying adolescents aged 12 to under 18 years with asthma who have had at least one severe asthma attack in the past year. This trial compares the effects of two inhalers a combination budesonidealbuterol inhaler and an albuterol-only inhaler, both used as needed. The goal is to see which inhaler better reduces severe asthma exacerbations over one year. Participants will be randomly assigned to use either the budesonidealbuterol inhaler or the albuterol inhaler as needed, in addition to their usual asthma maintenance therapy. The study lasts 52 weeks and includes a 7 to 28 day screening period before treatment and a safety follow-up period of 7 to 14 days after treatment ends. A separate pharmacokinetic sub-study involves a single visit after safety follow-up to evaluate drug levels after one dose of the budesonidealbuterol inhaler. During the study, participants will be regularly monitored for asthma attacks and medication use. Researchers will assess lung function, inhaler technique, and collect safety information including any adverse events. The main outcome is the annual rate of severe asthma exacerbations. Additional measures include time to first severe attack and corticosteroid use. Participants will complete peak flow measurements and have urine pregnancy tests if applicable. The total participation duration is approximately one year plus follow-up.

Age: 12Years - 17YearsAll GendersPhase 3
155 locations
C

Actively Recruiting

Researchers are evaluating the effectiveness of inclisiran, a subcutaneous injection given twice yearly, in preventing major cardiovascular and limb events in patients who have undergone percutaneous coronary or peripheral endovascular revascularization. This phase 4, randomized, double-blind, placebo-controlled study involves about 6,000 participants with symptomatic atherosclerotic cardiovascular disease, including coronary artery disease and peripheral artery disease. The goal is to understand how inclisiran can be used alongside usual care in real-world clinical settings. Participants will receive either inclisiran sodium 300 mg or a matching placebo by subcutaneous injection on Day 1, Month 3 Day 90, and every 6 months thereafter. Treatment starts within 14 days after a successful coronary or peripheral endovascular intervention. Both groups will continue their usual care as directed by their physicians. The study is event-driven and will continue until about 2,380 major events have occurred, with a treatment duration of up to approximately 45 months and an average follow-up of about 36 months. Throughout the study, participants will be regularly monitored for major adverse cardiovascular events and limb events, as well as other outcomes such as cardiovascular death, all-cause death, and venous thromboembolic events. Follow-up will last around 4 years. Assessments include clinical evaluations and ongoing observation to measure the impact of inclisiran compared to placebo while ensuring participant safety and adherence to the study protocol.

Age: 18Years +All GendersPhase 4
149 locations
M

Actively Recruiting

Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.

Age: 18Years +All Genders
2393 locations
R

Actively Recruiting

Researchers are evaluating the effect of olpasiran compared to a placebo on the risk of coronary heart disease death, heart attack, or urgent coronary revascularization in people at risk for a first major cardiovascular event who have elevated lipoproteina levels. This phase 3 study focuses on participants aged 50 to 105 years with multiple cardiovascular risk factors or evidence of atherosclerosis. Participants will be randomly assigned to receive either subcutaneous injections of olpasiran or a placebo. The study is designed as a double-blind, placebo-controlled trial, meaning neither participants nor researchers know who receives the active drug or placebo. The treatment period spans up to approximately 6.2 years, during which participants receive regular injections and monitoring. Throughout the study, participants will be assessed for the time until coronary heart disease death, myocardial infarction, or urgent coronary revascularization occurs. Additional measurements include changes in lipoproteina levels and monitoring of cardiovascular events, strokes, and safety through adverse event tracking. Participants will have regular evaluations over the treatment duration, ensuring close follow-up until study completion.

Age: 50Years - 105YearsAll GendersPhase 3
252 locations

1-10 of 13

1